IART vs MDXG
IART: A global medical technology leader specializing in neurosurgery and regenerative tissue reconstruction. MDXG: MiMedx is a regenerative medicine company specializing in placental tissue-based therapies for advanced wound care and surgical applications.
Side-by-side fundamentals
| Metric | IART | MDXG | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $13.41 | $4.62 | |
| Market cap | $1.0B | $673M | |
| P/E as of 2026-10-08 | n/a | 116.96 | |
| Net margin FY2025, SEC XBRL | -31.6% | +11.6% | MDXG higher |
| Gross margin FY2025, SEC XBRL | n/a | +82.6% | |
| Operating margin FY2025, SEC XBRL | -30.2% | +15.3% | MDXG higher |
| ROE FY2025, SEC XBRL | -49.5% | +18.9% | MDXG higher |
| ROA FY2025, SEC XBRL | -14.3% | +14.2% | MDXG higher |
| Debt / equity as of 2026-09-03 | 1.79 | 0.08 | MDXG lower |
| Revenue growth (YoY) as of 2026-09-03 | +1.6% | -2.4% | IART higher |
| Revenue CAGR (3y) SEC XBRL | +1.6% | +16.1% | MDXG higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 1.38 | 0.64 | |
| 1-year return as of 2026-10-08 close | -9.5% | -34.9% | IART higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.